Cialis approved in China for the treatment of active Crohn’s disease in adults
March 11, 2025
Source: drugdu
36
On March 10, AbbVie announced that the China National Medical Products Administration (NMPA) approved Cialis® for the treatment of adult patients with moderate to severe active Crohn's disease who have insufficient response, loss of response or intolerance to traditional treatment or biologics. The approval includes two dosage forms: risankizumab injection and risankizumab injection (subcutaneous injection). Cialis® is the world's first interleukin-23 (IL-23) inhibitor approved for adult patients with moderate to severe active Crohn's disease. After approval, it is also the first IL-23 inhibitor in China with a portable dosing device.
https://finance.eastmoney.com/a/202503103341127889.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- a milestone in the rise of domestic production March 12, 2025
- Heavy Ten Year Plan March 12, 2025
- Sino Biopharmaceuticals and Qingpu Biotechnology Reach Exclusive Cooperation Agreement March 12, 2025
- Sino Biopharmaceutical’s innovative drug clinical research results are internationally recognized March 12, 2025
- Yifang Biopharma D-2570 Psoriasis Phase II Clinical Study Results Released March 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
